Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma

Status:
Not yet recruiting

Trial end date:
2025-08-08

Target enrollment:

Participant gender:

To explore the efficacy of Tislelizumab combined with chemotherapy in the treatment of locally unresectable esophageal squamous cell carcinoma (ESCC)

Phase 2

Fuzhou General Hospital

Nedaplatin
Paclitaxel